Literature DB >> 16624626

Functional status of beta-2-adrenoceptor in isolated membranes of mature erythrocytes from patients with cirrhosis and oesophageal varices.

F T Hernández1, P Zapater, E De-Madaria, J M Palazón, S Pascual, J Irurzun, J Such, M Perez-Mateo, J F Horga.   

Abstract

Propranolol is a widely used drug for prophylaxis of variceal bleeding in patients with cirrhosis, but not all patients show an adequate clinical response. This variability may be in relation to beta adrenoceptor activity, but no information is available in this setting. Thirty-nine patients with advanced cirrhosis and presence of oesophageal varices were sequentially included. We studied the function of beta-2-adrenoceptor in isolated membranes of mature erythrocytes obtained from patients by measuring cyclic AMP (cAMP) production before and after isoproterenol. Blood samples obtained from 11 healthy volunteers were used as control. Patients showed a six-fold increase in the mean basal cAMP production as compared to healthy volunteers. Isoproterenol produced a small, non-significantly and highly variable increase in the AC activity in patients compared with controls. cAMP values remain stable after three months of continuous treatment with oral beta-blockers in both groups. Patients without antecedent of variceal bleeding or with an active alcohol intake showed a significantly higher isoproterenol effect. In conclusion, beta-receptor function in human erythrocytes membranes is altered in patients with cirrhosis and oesophageal varices.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16624626     DOI: 10.1016/j.vph.2006.03.001

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  3 in total

1.  Effects of dexmedetomidine on the deformability of erythrocytes in vitro and in anesthesia.

Authors:  Xiao-Ming Yang; Jun Liu; Jun Ji; Jie Xie
Journal:  Exp Ther Med       Date:  2014-03-27       Impact factor: 2.447

2.  Treatment with non-selective beta-blockers affects the systemic inflammatory response to bacterial DNA in patients with cirrhosis.

Authors:  Paula Gimenez; Irma Garcia-Martinez; Rubén Francés; Jose M Gonzalez-Navajas; Montserrat Mauri; Rocío Alfayate; Susana Almenara; Cayetano Miralles; Jose M Palazon; Fernando Carnicer; Sonia Pascual; José Such; José F Horga; Pedro Zapater
Journal:  Liver Int       Date:  2018-06-19       Impact factor: 5.828

3.  Zolmitriptan: a novel portal hypotensive agent which synergizes with propranolol in lowering portal pressure.

Authors:  Mercedes Reboredo; Haisul C Y Chang; Roberto Barbero; Carlos M Rodríguez-Ortigosa; Francisco Pérez-Vizcaíno; Asunción Morán; Mónica García; Jesús M Banales; Norberto Carreño; Félix Alegre; Ignacio Herrero; Jorge Quiroga; Jesús Prieto; Bruno Sangro
Journal:  PLoS One       Date:  2013-01-16       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.